Adenoid cystic cancers are rare tumors that affect the salivary glands and sometimes the upper airways. While surgery and radiation therapy help some patients, about 40 percent experience spread of the cancer to other parts of the body, and standard chemotherapy is typically not effective. The purpose of this study is to evaluate the safety and effectiveness of the drug axitinib in patients with adenoid cystic cancer that cannot be cured with surgery or radiation therapy or which has returned or spread despite prior treatment.
Axitinib is an oral medication which works by blocking certain proteins that play a role in the growth and progression of tumors. It is approved for treating a form of kidney cancer, but its use in adenoid cystic cancer is considered investigational.